U.S. Lung Cancer Screening Software Market, By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors) – Industry Trends and Forecast to 2030.
U.S. Lung Cancer Screening Software Market Analysis and Size
The National Cancer Institute estimates that over 228,150 new cases of lung cancer were reported in the United States in 2019. According to the Lung Cancer Alliance, the 5-year survival rate for lung cancer has decreased dramatically from stage 1 diagnosis (68%-92% survival) to stage 4 diagnosis (0%-10% survival). Thus these are the key factor driving the market is the increasing number of screening programmes around the world.
Data Bridge Market Research analyses that the lung cancer screening software market which is USD 14,214.86 thousand in 2022, is expected to reach USD 59,510.28 thousand by 2030, at a CAGR of 19.6% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
U.S. Lung Cancer Screening Software Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors)
|
|
Market Players Covered
|
Medtronic (Ireland), PenRad Technologies Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), Volpara Health Limited (U.S.), Lungview (U.S.), Siemens Healthcare Private Limited (Germany), Thynk Health (U.S.), E.ON SE (Germany), Nuance Communications, Inc. (U.S.), MeVis Medical Solutions AG (Germany), Optellum Ltd (U.K.), MyCareWare (U.S.), ProVation Medical, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Lung cancer screening can be used to determine the stage of the disease. The most advised method for detecting lung cancer is through CT screening. It is anticipated that increased usage of this technology would increase the demand for sophisticated software for lung cancer screening. Using this software, healthcare workers may efficiently gather, organize and transfer data to clinicians and patients while managing patient involvement in lung screening programmes. Additionally, this programme makes it possible to identify patients who are at risk and streamlines data flow with linked electronic health records.
U.S. Lung Cancer Screening Software Market Dynamics
Drivers
- Increase in prevalence of lung cancer cases globally
The main cause of death for both men and women is lung cancer. According to World Cancer Research Fund International, lung cancer is the second most frequent cancer worldwide. In both men and women, it is the second most frequent kind of cancer. Lung cancer saw an increase of almost 2.2 thousand new cases in 2020. A major element in the market's growth is the rising incidence of lung cancer, which makes it necessary to employ lung cancer screening software for early diagnosis.
- Increase in awareness regarding the benefits of early diagnosis and frequent screening
The market growth is predicted to be boosted by increased awareness campaigns for lung cancer by public, non-profit, and private organizations. These programmes work to promote research, lessen stigma and prejudice, and prevent sickness. Lung cancer has become a topic of greater public awareness. People are aware of lung cancer and how treatable it is if detected early because to the numerous awareness campaigns run by various organizations. As a result, increasing public awareness is fuelling market expansion.
Opportunities
- Government initiatives were undertaken to implement screening programs for various diseases
Cancer's global burden is increasing, putting financial, emotional, and physical strain on health-care systems, products, families, and individuals. Many types of cancer have a higher survival rate in countries with strong health systems, owing to survivorship, quality care, increased awareness, and easily accessible early detection. Through the National Comprehensive Cancer Control Program (NCCCP), the Centers for Disease Control and Prevention, tribes and US-Pacific islands and territories will form or support alliances to combat cancer in their communities. As a result of these initiatives, more audiences are educated and more consciously dispersed, prompting the global audience to take additional precautions and conduct preventive examinations, thereby promoting the market.
Restraints/Challenges
- Issues related to the availability of software
Both the accessibility of lung cancer screening software in underdeveloped countries and issues/barriers to effective and efficient lung cancer screening exist. Changing opinions about screening's efficacy, nihilism brought by historically poor lung cancer treatment outcomes, lack of training, and the need for local authorities' or a country's medical device regulatory body's approval are all problems. All of these issues cause the product's launch and availability to be delayed. Furthermore, the demand for lung cancer screening software is hampered by technical issues with the available software acting as a market restraint.
This lung cancer screening software market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer screening software market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Lung Cancer Screening Software Market
COVID-19 presented healthcare providers with new and unfamiliar challenges in providing patient care. Many non-essential but important services, such as lung cancer screening, were temporarily suspended. Healthcare institutions faced unprecedented challenges in terms of scheduling, patient monitoring and follow-up on patient-service communication during COVID-19 and when services could be safely continued. In many situations, COVID-19 caused screening programmes for lung cancer to be delayed by several months and made management and scheduling teams' jobs more difficult. It is anticipated that the COVID-19 crisis will greatly lessen the stigma attached to cancer screening, even though it brought attention to the necessity of respiratory support.
Recent Developments
- In 2022, GE Healthcare launched their most advanced ultrasound. This latest addition to GE Healthcare's award-winning Women's Health portfolio employs graphic-based beam former technology, which produces higher-quality images and provides greater imaging flexibility. With this product, the company strengthened its position as a provider of products and services to healthcare institutions.
- In 2021, Thynk Health announced a collaboration with Infervision to fight lung cancer using the most advanced technologies available. It allows for lung cancer screening and pulmonary nodule management. With this collaboration, the company expanded its market presence.
U.S. Lung Cancer Screening Software Market Scope
The lung cancer screening software market is segmented on the basis of product, mode of delivery, platform, purchase mode, distribution channel, type, end-user and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Mode of Delivery
- Cloud Based Solutions
- On-Premise Solutions
- Web Based Solutions
Product
- Lung Cancer Screening Radiology Solution
- Lung Cancer Screening Patient Management Software
- Nodule Management Software
- Data Collection and Reporting
- Patient Coordination and Workflow
- Lung Nodule Computer Aided Detection
- Pathology and Cancer Staging
- Statistical Audit Reporting
- Screening PACS
- Practice Management
- Audit Log Tracking
Type
- Computer-Assisted Screening
- Traditional Screening
Application
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
Platform
- Standalone
- Integrated
Purchase Mode
- Institutional
- Individual
End User
- Oncology Centers
- Hospitals
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct Tender
- Third Party Distributors
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The lung cancer screening software market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer screening software market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer screening software market. The data is available for historic period 2011-2021.
Competitive Landscape and Lung Cancer Screening Software Market Share Analysis
The lung cancer screening software market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer screening software market.
Some of the major players operating in the lung cancer screening software market are:
- Medtronic (Ireland)
- PenRad Technologies Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- Volpara Health Limited (U.S.)
- Lungview (U.S.)
- Siemens Healthcare Private Limited (Germany)
- Thynk Health (U.S.)
- E.ON SE (Germany)
- Nuance Communications, Inc. (U.S.)
- MeVis Medical Solutions AG (Germany)
- Optellum Ltd (U.K.)
- MyCareWare (U.S.)
- ProVation Medical, Inc. (U.S.)
SKU-